Cargando…

Differential Characteristics and Prognosis of PD-L1–Positive Endometrial Carcinomas: A Retrospective Chart Review

Women with endometrial carcinomas that express PD-L1 may respond better to immunotherapy. Our aim was to investigate the differential characteristics of PD-L1–positive endometrial carcinomas and the prognostic significance of PD-L1. We performed a retrospective chart review of 231 women with endomet...

Descripción completa

Detalles Bibliográficos
Autores principales: Amarin, Justin Z., Mansour, Razan, Al-Ghnimat, Sura, Al-Hussaini, Maysa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540374/
https://www.ncbi.nlm.nih.gov/pubmed/34685418
http://dx.doi.org/10.3390/life11101047
_version_ 1784588971768020992
author Amarin, Justin Z.
Mansour, Razan
Al-Ghnimat, Sura
Al-Hussaini, Maysa
author_facet Amarin, Justin Z.
Mansour, Razan
Al-Ghnimat, Sura
Al-Hussaini, Maysa
author_sort Amarin, Justin Z.
collection PubMed
description Women with endometrial carcinomas that express PD-L1 may respond better to immunotherapy. Our aim was to investigate the differential characteristics of PD-L1–positive endometrial carcinomas and the prognostic significance of PD-L1. We performed a retrospective chart review of 231 women with endometrial carcinomas who were managed at King Hussein Cancer Center (2007–2016) and performed immunohistochemistry for MLH1, PMS2, MSH2, MSH6, p53, and PD-L1. Overall, 89 cases (38.5%) were MMR-deficient. PD-L1 was expressed in 49 cases (21.2%) and its expression was significantly associated with MLH1/PMS2 deficiency (p = 0.044) but not MSH2/MSH6 deficiency (p = 0.59). p53 was mutant in 106 cases (46.5%), and its mutation was significantly associated with MMR proficiency (p < 0.001) but not PD-L1 expression (p = 0.78). In women with endometrioid adenocarcinomas, PD-L1 expression was significantly associated with the Fédération Internationale de Gynécologie et d′Obstétrique (FIGO) grade (p = 0.008). Overall, PD-L1 expression did not significantly predict overall survival in unadjusted or adjusted analyses (p = 0.92 and 0.54, respectively). In conclusion, tumors with MLH1/PMS2 loss and high-grade endometrioid adenocarcinomas were more likely to express PD-L1 in tumor cells. Further research is required to investigate whether the presence of either characteristic signals a higher likelihood of a favorable response if immunotherapy is administered.
format Online
Article
Text
id pubmed-8540374
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85403742021-10-24 Differential Characteristics and Prognosis of PD-L1–Positive Endometrial Carcinomas: A Retrospective Chart Review Amarin, Justin Z. Mansour, Razan Al-Ghnimat, Sura Al-Hussaini, Maysa Life (Basel) Article Women with endometrial carcinomas that express PD-L1 may respond better to immunotherapy. Our aim was to investigate the differential characteristics of PD-L1–positive endometrial carcinomas and the prognostic significance of PD-L1. We performed a retrospective chart review of 231 women with endometrial carcinomas who were managed at King Hussein Cancer Center (2007–2016) and performed immunohistochemistry for MLH1, PMS2, MSH2, MSH6, p53, and PD-L1. Overall, 89 cases (38.5%) were MMR-deficient. PD-L1 was expressed in 49 cases (21.2%) and its expression was significantly associated with MLH1/PMS2 deficiency (p = 0.044) but not MSH2/MSH6 deficiency (p = 0.59). p53 was mutant in 106 cases (46.5%), and its mutation was significantly associated with MMR proficiency (p < 0.001) but not PD-L1 expression (p = 0.78). In women with endometrioid adenocarcinomas, PD-L1 expression was significantly associated with the Fédération Internationale de Gynécologie et d′Obstétrique (FIGO) grade (p = 0.008). Overall, PD-L1 expression did not significantly predict overall survival in unadjusted or adjusted analyses (p = 0.92 and 0.54, respectively). In conclusion, tumors with MLH1/PMS2 loss and high-grade endometrioid adenocarcinomas were more likely to express PD-L1 in tumor cells. Further research is required to investigate whether the presence of either characteristic signals a higher likelihood of a favorable response if immunotherapy is administered. MDPI 2021-10-06 /pmc/articles/PMC8540374/ /pubmed/34685418 http://dx.doi.org/10.3390/life11101047 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Amarin, Justin Z.
Mansour, Razan
Al-Ghnimat, Sura
Al-Hussaini, Maysa
Differential Characteristics and Prognosis of PD-L1–Positive Endometrial Carcinomas: A Retrospective Chart Review
title Differential Characteristics and Prognosis of PD-L1–Positive Endometrial Carcinomas: A Retrospective Chart Review
title_full Differential Characteristics and Prognosis of PD-L1–Positive Endometrial Carcinomas: A Retrospective Chart Review
title_fullStr Differential Characteristics and Prognosis of PD-L1–Positive Endometrial Carcinomas: A Retrospective Chart Review
title_full_unstemmed Differential Characteristics and Prognosis of PD-L1–Positive Endometrial Carcinomas: A Retrospective Chart Review
title_short Differential Characteristics and Prognosis of PD-L1–Positive Endometrial Carcinomas: A Retrospective Chart Review
title_sort differential characteristics and prognosis of pd-l1–positive endometrial carcinomas: a retrospective chart review
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540374/
https://www.ncbi.nlm.nih.gov/pubmed/34685418
http://dx.doi.org/10.3390/life11101047
work_keys_str_mv AT amarinjustinz differentialcharacteristicsandprognosisofpdl1positiveendometrialcarcinomasaretrospectivechartreview
AT mansourrazan differentialcharacteristicsandprognosisofpdl1positiveendometrialcarcinomasaretrospectivechartreview
AT alghnimatsura differentialcharacteristicsandprognosisofpdl1positiveendometrialcarcinomasaretrospectivechartreview
AT alhussainimaysa differentialcharacteristicsandprognosisofpdl1positiveendometrialcarcinomasaretrospectivechartreview